Innate immunity in tumour immunoediting and immunosurveillance

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Cancer immunotherapy, including immune checkpoint blockade (ICB) and CAR T cells, has shown success but is ineffective against most solid tumors.
• Tumors employ various mechanisms to evade immune detection and destruction, necessitating novel therapeutic approaches.
• Understanding tumor evolution and immune evasion strategies is crucial for developing more effective cancer treatments.

Purpose of the Study:

• To explore the role of innate immunity in anti-tumor responses.
• To identify strategies for enhancing tumor immune responsiveness.
• To discuss the potential of harnessing innate immunity for improved cancer immunotherapy.

Main Methods:

• Reviewing current research on cancer immunotherapy and tumor immune evasion.
• Analyzing mechanisms of tumor immunoediting and immune suppression.
• Investigating the interplay between innate immunity and anti-tumor responses.

Main Results:

• Tumors suppress antigen processing and presentation to evade T cell recognition.
• Evolving tumors also repress innate immune genes that signal danger to immune cells.
• Innate immunity plays a critical role in initiating and sustaining anti-tumor immune responses.

Conclusions:

• Innate immunity is a key factor in controlling tumor growth and response to immunotherapy.
• Harnessing innate immune pathways presents a promising avenue for overcoming resistance to current cancer therapies.
• Targeting innate immunity could potentially make a wider range of cancers responsive to immunotherapy.